From: Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
ITT population | (n=17) | Baseline | 6 months | 12 months | 24 months |
---|---|---|---|---|---|
50% reduction from baseline 1 | n (%) [95%CI] | - | 11 (64.7%) | 14 (82.4%) | 10 (58.82%) |
[38.3% to 85.8%] | [56.6% to 96.2%] | [32.92% to 81.56%] | |||
30% reduction from baseline 2 | n (%) [95%CI] | - | 15 (88.2%) | 17 (100.0%) | 14 (82.4%) |
[63.6% to 98.5%] | [83.8% to 100.0%] | [56.6% to 96.2%] | |||
Adjusted baseline change (%) | LSMean [95%CI] | 0 | −55.18 [−65.85 to −44.51] | −66.38 [−75.77 to −56.98] | −62.08 [−72.70 to −51.46] |
6 vs 12 months | - | Ref | −11.20 [−5.61 to −16.78] p<0.001 | - | |
12 vs 24 months | - | - | Ref | 4.30 [−2.61 to 11.21] p=0.205 | |
Absolute values (cm3) | LSMean [95%CI] | 62.65 [24.05 to 101.25] | 28.62 [12.91 to 44.33] | 23.07 [8.29 to 37.84] | 21.68 [11.30 to 32.06] |
0 vs 6 months | Ref | −34.03 [−9.90 to −58.16] p=0.008 | - | - | |
0 vs 12 months | Ref | - | −39.58 [−14.74 to −64.42] p=0.004 | - | |
0 vs 24 months | Ref | - | - | −40.97 [−11.15 to −70.79] p=0.010 |